**Name of Journal:** *World Journal of Psychiatry*

**Manuscript NO:** 70353

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients**

Yu L *et al*. Mental health in LOMG

Lu Yu, Li Qiu, Hao Ran, Qian Ma, Ya-Ru Lu, Wei-Bin Liu

**Lu Yu, Li Qiu, Qian Ma, Ya-Ru Lu, Wei-Bin Liu,** Department of Neurology, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, Guangdong Province, China

**Hao Ran,** School of Pharmaceutical Science, Sun Yat-sen University, Guangzhou 510006, Guangdong Province, China

**Author contributions:** Liu WB was the guarantor and contributed to the conception of the study; Yu L and Qiu L participated in the acquisition, analysis, and interpretation of the data, and drafted the initial manuscript; Ran H, Ma Q, Lu YR revised the article critically for important intellectual content.

**Supported by** the National Natural Science Foundation of China, No. 81873772 and 81971754; National Natural Science Foundation Key International (Regional) Cooperation Research Project, No. 81620108010; Clinical Study of 5010 Planned Project Sun Yat-sen University, No. 2010003; Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, No. 2020B1212060017; Guangdong Provincial Clinical Research Center for Neurological Diseases, No. 2020B1111170002; the Southern China International Cooperation Base for Early Intervention and Functional Rehabilitation of Neurological Diseases, No. 2015B050501003 and 2020A0505020004.

**Corresponding author: Wei-Bin Liu, MD, Chief Physician, Professor,** Department of Neurology, National Key Clinical Department and Key Discipline of Neurology, the First Affiliated Hospital of Sun Yat-sen University, No. 58 Zhongshan 2nd Road, Guangzhou 510080, Guangdong, China. liuwb@mail.sysu.edu.cn

**Received:** August 1, 2021

**Revised:** November 26, 2021

**Accepted:** February 22, 2022

**Published online:** March 19, 2022

**Abstract**

BACKGROUND

Mental disorders are common comorbidities among individuals with neurological diseases, and the prevalence of depressive and anxiety-related symptoms in newly referred patients at neurology outpatient clinics is high. There have been few studies on the mental health of patients with late-onset myasthenia gravis (MG).

AIM

To examine the relationship between clinical features and the mental health symptoms within late-onset MG patients.

METHODS

A total of 105 patients diagnosed with MG were recruited consecutively from a neuromuscular outpatient clinic between December 2020 and February 2021. Patients were classified into two groups: early-onset MG (age at onset < 50 years, *n* = 63) and late-onset MG (age at onset ≥ 50 years, *n* = 42). Social demographic data and information about marital status, education level, clinical symptoms, serum antibody levels, and therapies used were collected for all participants. Participants were also evaluated using the Myasthenia Gravis Composite scale, the Myasthenia Gravis Activities of Daily Living scale, the Myasthenia Gravis Quality of Life 15 (MG-QOL-15) questionnaire, the 17-item version of the Hamilton Depression Rating Scale (HAM-D) and the Hamilton Anxiety Rating Scale (HAM-A). The relationship between clinical features and mental health in late-onset MG patients was examined using multivariate logistic regression analyses.

RESULTS

Late-onset MG patients were more prone to dyspnea, had higher levels of serum anti-acetylcholine receptor antibodies, and higher total scores on the MG-QOL-15, HAM-D, and HAM-A questionnaires, than early-onset MG patients had (*P* < 0.05). Among those with late-onset MG, female patients had higher total HAM-D and HAM-A scores than male patients had (*P* < 0.05). High scores on the QOL-15 questionnaire were associated with higher incidences of anxiety and depression, and the association was found to be independent after adjusting for confounding risk factors. In the late-onset subgroup, the areas under the receiver operating characteristic curves for the MG-QOL-15 score-based diagnostic accuracy for anxiety and depression state were 0.816 (*P* = 0.001) and 0.983 (*P* < 0.001), respectively.

CONCLUSION

Higher MG-QOL-15 scores were a risk factor for anxiety and depression in late-onset MG, and women with late-onset MG were more likely to have anxiety and depression than men were.

**Key Words:** Mental health; Late-onset myasthenia gravis; Anxiety; Depression

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Yu L, Qiu L, Ran H, Ma Q, Lu YR, Liu WB. Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients. *World J Psychiatry* 2022; 12(3): 470-482

**URL:** <https://www.wjgnet.com/2220-3206/full/v12/i3/470.htm>

**DOI:** <https://dx.doi.org/10.5498/wjp.v12.3.470>

**Core tip:** Mental disorders are the common comorbidities among myasthenia gravis (MG) patients in older age. In this study, we found that female patients with late-onset MG were more susceptible to anxiety and depression than their male counterparts, and that higher scores on the Myasthenia Gravis Quality of Life 15 questionnaire were an independent risk factor for anxiety and depression in patients with late-onset MG. This is the first report detailing the relationship between clinical features and mental health in the subgroup of MG patients with late disease onset.

**INTRODUCTION**

Myasthenia gravis (MG) is an autoimmune disorder that is mainly caused by autoantibodies binding to nicotinic acetylcholine receptors (AChRs) at muscle endplates, and is characterized by skeletal muscle fatigability and weakness[1,2]. MG is also associated with emotional, cognitive, and behavioral symptoms[3].

Mental disorders are the most common comorbidities among individuals with neurological diseases, and the prevalence of depressive and anxiety-related symptoms in newly referred patients at neurology outpatient clinics is high[4]. MG is an autoimmune disease that can lead to disability. The global prevalence of MG is roughly 40-180 cases per 1 million individuals[5]. However, there are limited data on the relationship between mental disorders and MG, especially in patients with late-onset forms of the disease. Furthermore, because myasthenic symptoms of MG may overlap with somatic symptoms of depression and anxiety[6], such as fatigue or shortness of breath, which are also common in mental disorders, and facial weakness and blepharoptosis generally convey an impression of depression and apathy[7], comorbidities accompanied by mental and myasthenic symptoms may be misdiagnosed, thus the need to focus on both mental and physical therapies has been highlighted[8,9].

Mental disorders have often been reported; the incidence is up to 59% of MG patients, with depression being the most common disorder, followed by anxiety and hypochondria[10]. The unpredictable progression, chronic course and long-term treatment for MG can lead to limitations and reductions in quality of life (QOL)[11-13], which were found to predispose to psychological stress[7]. There is a questionnaire specifically aimed at assessing QOL among MG patients (Myasthenia Gravis Quality of Life 15-item (MG-QOL-15) scale, including 15 test items that address MG-specific social functioning and uses five response options, based on which QOL can be effectively rated[14,15]. The measures of MG-QOL-15 try to capture patients’ appraisal of and satisfaction with their current level of functioning compared to what they perceive to be possible or ideal, and higher scores on the MG-QOL-15 questionnaire were indicative of more severe clinical cases to some extent[13].

Longer disease duration, severity of disease, and MG-induced respiratory failure may contribute to the increased rates of depression[16,17]. Compromised swallowing and communication abilities, unpredictable and fluctuating nature of respiratory dysfunction suggests concerning risk factors for developing anxiety among MG patients[7,16-18]. Fewer work restrictions could be protective factors for developing mental disorders in the limited observational studies[19]. Late-onset MG occurring in older adults is more difficult to manage mainly because of the multiple comorbidities[20,21] and MG with late disease onset is on the rise in recent years[22]. Due to the frequent occurrence of comorbidities in older people that might be confused with MG symptoms[23], awareness of the occurrence of mental disorders in older age groups of MG is needed for earlier intervention and thus a better outcome. To this end, this cross-sectional study aimed to investigate the relationship between clinical features and mental health in patients with late-onset MG.

**MATERIALS AND METHODS**

***Study design and participants***

This cross-sectional study was conducted in The First Affiliated Hospital of the Sun Yat-sen University, in Guangzhou, China. A total of 105 patients diagnosed with MG were recruited consecutively from a neuromuscular outpatient clinic between December 2020 and February 2021. Clinical data were collected, and scores on clinical scales were procured through face-to-face evaluations with professional neurologists. This study was approved by the Ethics Committee of The First Affiliated Hospital of the Sun Yat-sen University. We obtained informed consent from all patients prior to the scale-based clinical examinations.

***Inclusion and exclusion criteria***

All participants were diagnosed with MG according to international consensus-based guidelines[24]. This study included patients who met the following criteria: (1) diagnosed with MG; (2) aged ≥ 16 years; and (3) ability to fully cooperate during clinical scale-based evaluations. Patients were excluded if they: (1) were under treatment with antianxiety and/or antidepressant drugs; and (2) had incomplete data.

***Clinical data and scales***

We collected data on sociodemographic characteristics, inducing factors, comorbidities, specific clinical features (*i.e.*, disease duration, Myasthenia Gravis Foundation of America Classification, symptoms at first evaluation, and mental status), details of serum antibodies levels [*i.e.*, levels of anti-AChR/muscle-specific tyrosine kinase (MuSK) antibodies], and immunotherapy history. Patients were independently examined using the Myasthenia Gravis Composite (MGC) scale, the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, the MG-QOL-15 questionnaire, the 17-item version of the Hamilton Depression Rating Scale (HAM-D), and the Hamilton Anxiety Rating Scale (HAM-A) by two neurologists (both of whom were qualified to perform these evaluations).

The MGC scale[25] is composed of 10 items that measure symptoms and signs of MG, with a maximum score of 50 points, the reliability coefficient of the MGC scale was 98%, indicating excellent test-retest reliability. The MG-ADL scale[26] is composed of eight questions, aims to assess disability of ocular (2 items), bulbar (3 items), respiratory (1 item), and limb (2 items), with each response graded from 0 (normal) to 3 (most severe), and the total score ranges from 0 to 24, reliability coefficient was 93.7%. The MG-QOL-15 consists of 15 items: mobility (9 items), symptoms (3 items), general contentment (1 item), and emotional well-being (2 items)[27], with each response graded from 0 (not at all) to 4 (very much), and total scores of up to 60 points, the Chinese MG-QOL-15 had excellent internal consistency (Cronbach’s α = 0.928). Higher scores on MGC, MG-ADL, or MG-QOL-15 scales were indicative of more severe clinical cases. The HAM-A and HAM-D scales consist of 14 and 17 items, respectively, and are used to measure mental health symptoms[28,29]. The total scores are 56 (for the HAM-A) and 53 (for the HAM-D), and total HAM-A scores were classified as no (< 7), potential (7-13), assured (14-29), and severe (> 29) anxiety. Total HAM-D scores were classified as no (< 7), potential (7-17), assured (17-24), and severe (> 24) depression, the Cronbach’s coefficient of them was > 0.8, indicating good internal consistency. The above questionnaires and scales were administered in the Chinese language, and are all reliable, valid, and widely used[30-33].

***Groups***

Participants were categorized into the following subgroups according to their age at disease onset[34]: early-onset MG (age at onset < 50 years, *n* = 63) and late-onset MG (age at onset ≥ 50 years, *n* = 42). HAM-A scores ≥ 7 and HAM-A scores < 7 were considered to be indicative of anxiety and nonanxiety states, while HAM-D scores ≥ 7 and HAM-D scores < 7 were classified to be depressive and nondepressive states, respectively[35,36]. Patients were considered seropositive for anti-AChR antibodies if their titers were > 0.45 nmol/L on ELISA. They were deemed seropositive for anti-MuSK antibodies if their titers were > 0.05 nmol/L on a radioimmunoassay. All test reagents were purchased from RSR Ltd. (Cardiff, United Kingdom.

***Statistical analysis***

Statistical analyses were performed using SPSS version 25 software (IBM, Chicago, United States) and GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA). Categorical data were presented as counts and percentages, and were analyzed using Fisher’s exact test or *χ*2 test. Numerical data were presented as medians and interquartile ranges (partial distribution), and compared using the Mann-Whitney *U* test. Correlations were estimated with Pearson or Spearman correlation coefficients. Clinical determinants of anxiety and depression were used in multivariate logistic regression analyses, while gender, age at onset, body mass index (BMI), anti-AChR antibody levels, and MG-QOL15 scores were considered confounding risk factors. Receiver operating characteristic (ROC) curves were drawn to evaluate the value of MG-QOL-15 scores for diagnosing anxiety and depression. Significance was accepted if *P* values were < 0.05, and are denoted as a*P* < 0.05, b*P* < 0.01, and c*P* < 0.001.

**RESULTS**

***Baseline characteristics***

Patients with late-onset MG (age at onset ≥ 50 years) accounted for 40.0% (*n* = 42) of the 105 patients, and those with early-onset MG (age < 50 years) accounted for 60.0% (*n* = 63). Among the patients with late-onset MG, 45.24% were women, and 54.76% were men. Among the early-onset MG patients, 58.73% were women, and 41.27% were men.

The medians (interquartile ranges) of HAM-A scores were 5 (5.5) in early-onset patients and 8.5 (7.5) in late-onset patients. These scores were significantly different between the two groups (*P* < 0.001; Figure 1A). The HAM-D scores were 7 (8) and 10.5 (7.75) in early-onset and late-onset patient groups, respectively, and there was a significant difference between the two groups (*P* = 0.018; Figure 1B). There were also significant differences in BMI, disease duration, dyspnea symptoms, anti-AChR antibody levels, and MG-QOL-15 scores between the two groups (*P* < 0.05). HAM-A and HAM-D scores were significantly higher in female patients with late-onset MG than in those with early-onset MG (*P* < 0.001 and *P* = 0.001, respectively), but no significant differences were observed when only male patients were considered in these analyses (*P* = 0.192 and *P* = 0.731, respectively; Figure 2A and B). Baseline characteristics of the early-onset and late-onset groups are shown in Table 1.

***Correlation between clinical features and age at onset, assessed using Pearson or Spearman correlation analysis***

There was a positive correlation between age at onset and BMI (*r* = 0.41, *P* < 0.001), anti-AChR antibody levels (*r* = 0.31, *P* = 0.001), MG-QOL-15 scores (*r* = 0.32, *P* = 0.001), HAM-A scores (*r* = 0.41, *P* < 0.001), and HAM-D scores (*r* = 0.26, *P* = 0.007). However, there was a negative correlation between age at onset and disease duration (*r* = −0.59, *P* < 0.001). Correlations between all clinical features and age at onset are detailed in Table 2.

***Clinical determinants of anxiety and depression in MG patients, measured using logistic analysis***

Based on results from univariate analyses as well as previous literature[14-19], variables that may be relevant for mental health outcomes (gender, age at onset, BMI, anti-AChR antibody levels, and MG-QOL-15 scores) were included in a logistic regression model. No multicollinearity amongst the variables was found (variance inflation ranged from 1.072 to 1.536; tolerance ranged from 0.651 to 0.933) (Supplementary Table 1).

When the incidence of anxiety and depression were included as independent variables in the logistic analysis, they were associated with age at onset and MG-QOL-15 when other confounders were not considered. However, only MG-QOL15 scores were found to be independently associated with an increased risk of anxiety [odds ratio (OR) 1.10, 95%CI 1.04-1.15, *P* < 0.001) after adjusting for possible confounds (including gender, age at onset, BMI, and anti-AChR antibody levels). MG-QOL-15 scores were also significantly associated with the incidence of depression in MG patients (OR 1.20, 95%CI: 1.10-1.30, *P* < 0.001) (Table 3).

***Diagnostic value of MG-QOL15 scores for examining mental health in late-onset MG patients***

When multivariate analysis was performed after adjusting for related confounds, MG-QOL-15 scores were found to be independent risk factors for anxiety and depression. In patients with late-onset MG, the median (interquartile ranges) MG-QOL-15 scores in the nonanxiety and anxiety groups were 8 (10.5) and 20 (17), respectively, and there were significant differences between the two groups (*P* < 0.001). Similarly, MG-QOL-15 scores were significantly different between the depression and nondepression groups (*P* < 0.001; Supplementary Figures 1A and 2A). We also examined whether MG-QOL-15 scores could help to diagnose or predict anxiety/depression state in late-onset MG patients using ROC curves [the larger the area under the ROC curve (AUC), the higher the diagnostic accuracy], and the smallest point that maximizes the value of (sensitivity + specificity − 1) is calculated as the cut-off value, which would lead to the maximum degree of classification for anxiety/depression state. In our study, the AUC for MG-QOL-15 scores at a cut-off value of 14.5 in the anxiety group was 0.816 (*P* = 0.001), and the sensitivity-specificity was 75.86% and 84.62%, respectively (Supplementary Figure 1B). The AUC for MG-QOL-15 scores at a cut-off value of 14.5 in the depression group was 0.983 (*P* < 0.001), and the sensitivity-specificity were 70.59% and 100%, respectively (Supplementary Figure 2B).

**DISCUSSION**

In the current study, late-onset MG patients had higher total scores on the MG-QOL-15, HAM-A, and HAM-D scales compared with early-onset group MG patients, and there was a positive linear correlation between age at onset and MG-QOL-15 scores, HAM-A scores, and HAM-D scores. These results support the idea that late-onset MG is correlated with more severe impairments to patients’ QOL and mental state. MG has previously been demonstrated to affect QOL, as well as mental and physical health[37]. Factors that influence QOL in MG include trouble with eyesight, skeletal muscle weakness, activity limitations, and unhealthy mental state[38,39]. MG-QOL-15 scales have also previously been applied to assess MG-related dysfunction[40]. Several studies reported that MG-QOL-15 scores in MG patients are highly and positively correlated with scores on the HAM-A and HAM-D scales[38,41,42]. These findings supported the notion that low QOL correlates with poor mental health in MG patients.

We also found that female patients with late-onset MG were more susceptible to anxiety and depression. It is important to examine what factors are related to the mental health of patients with late-onset MG and why there are sex-related differences. The prevalence of depression and anxiety is higher among women than men. This difference in mental disorders is the result of a complex interplay between genetic, hormonal and psychosocial factors[43-45]. Some studies have shown that women rather than men carrying the SS genotype of serotonin transporter gene-linked promoter region (5-HTTLPR) more easily develop depressive symptoms under a negative environment[46,47]. Female patients with MG tend to have more severe cases of the disease, and may also be affected by hormonal changes associated with menstruation, pregnancy, and/or postpartum fluctuations in hormone levels[48-50]. Previous studies have reported that the use of glucocorticoids is associated with changes in physical appearances, leading to conditions such as moon face and/or central obesity, which may have greater negative sociopsychological effects on women with MG than men. Moreover, some patients with late-onset MG do not have positive responses to medication, and some are intolerant to treatment, which can result in refractory conditions[51]. Female patients with late-onset MG may endure the adverse effects of comorbidities longer than their male counterparts, which would contribute to poorer QOL[52]. These factors could explain why female MG patients had higher susceptibility to anxiety and depression than male patients.

Our study showed that MG-QOL-15 scores were independently associated with an increased risk of anxiety and depression when gender, age at onset, BMI, and anti-AChR antibody levels were adjusted for in a multivariate analysis. We found that the ORs (95%CIs) of MG-QOL-15 scores for the anxiety and depression groups were 1.10 (1.04-1.15, *P* < 0.001) and 1.20 (1.10-1.30, *P* < 0.001), respectively, indicating that under the same conditions of gender, age at onset, and other factors, the odds of anxiety state increased by 10% and depression state increased by 20% for each increase in MG-QOL-15 scores, and high MG-QOL-15 scores were indeed a risk factor for anxiety/depression state. Previous studies have demonstrated that lower perceived QOL is highly correlated with mental impairment in MG patients[9,53,54]. In late-onset groups, the areas under the ROC curves for MG-QOL-15 scores at a cutoff value of 14.5 in the anxiety and depression groups were 0.816 and 0.983, respectively, which suggested that MG-QOL-15 scores had good diagnostic accuracy for the mental disorders, at least among late-onset MG patients. Our data revealed that MG-QOL-15 score cutoff of 14.5 could be a good indicator for poor mental health in need of attention among late-onset MG patients. Further research is needed for fine-tuning this threshold.

Some research has also reported that patients with MG who received thymectomy or proper immunosuppressive therapy had improved physical health and decreased disability symptoms, which indirectly improved mental health[55,56]. However, our study found that the rate of thymectomy and immunosuppressive treatment was comparable between early-onset and late-onset groups, but that late-onset MG patients had significantly higher levels of serum anti-AChR antibodies and were more prone to dyspnea. The proportion of overweight patients in the late-onset group was greater than that in the early-onset group. This pattern could be related to older age, which contributes to reductions in physical activity and possibly susceptibility to the adverse effects of glucocorticoids[57]. Compared to early-onset MG patients, higher anti-AChR antibody titers were reported in late-onset MG patients[57,58], which may partly be due to immune dysregulation, including age-related decreases in immunocompetence and increases in the production of autoantibodies[59,60]. Bulbar[23] and ocular symptoms[61] have been previously reported to be more common in late-onset MG patients. However, we found no differences in extraocular or limb muscle involvement between the two groups. Genetic factors may influence these results, since a similar study that reported a higher occurrence of ocular symptoms in late-onset patients also reported a higher proportion of women in the late-onset group[62].

There were some limitations to our study. First, limits in our sampling method make it difficult to draw firm conclusions. Second, our study had a prospective design, so further follow-up and particularly studies that include healthy control groups are needed to validate the results. However, our study had some advantages. For example, all included patients were enrolled from the same neuromuscular outpatient clinic. Thus, they received prompt and high-quality clinical scale evaluations that were performed by well-qualified and trained professionals, which ensured the integrity and authenticity of the data.

**CONCLUSION**

Our research showed that female patients with late-onset MG were more susceptible to anxiety and depression than their male counterparts, and that higher MG-QOL-15 scores were an independent risk factor for anxiety and depression in patients with late-onset MG. To our knowledge, this is the first report detailing the relationship between MG-QOL-15 scores and mental health in the subgroup of MG patients with late disease onset. Thus, this association warrants further exploration in future research.

**ARTICLE HIGHLIGHTS**

***Research background***

The prevalence of depressive and anxiety-related symptoms in newly referred patients at neurology outpatient clinics is high, and mental state of myasthenia gravis (MG) patients were seldom assessed by mental scales routinely, so little is known about the exact relationship between MG and mental disorders that often accompany it.

***Research motivation***

Due to the frequent occurrence of comorbidities in older people that might be confused with MG symptoms, awareness of mental disorders in older age groups of MG is needed for earlier intervention and thus a better outcome. In the present, there have been few studies on the mental health of patients with late-onset MG, so we conducted this study to assess the related factors for developing mental disorders in the subgroup of MG patients.

***Research objectives***

This study aimed to investigate the relationship between clinical features and mental health in patients with late-onset MG, in addition to treating physical symptoms, attention should also be paid to mental disorders in late-onset MG patients.

***Research methods***

A total of 105 patients diagnosed with MG were recruited consecutively from a neuromuscular outpatient clinic between December 2020 and February 2021 in our hospital. Clinical data including sociodemographic, neurological and mental information were collected, and scores on clinical scales were procured through face-to-face evaluations with professional neurologists. The relationship between clinical features and mental health in late-onset MG patients was examined using multivariate logistic regression analyses.

***Research results***

Late-onset MG patients had higher total scores on the MG Quality of Life 15 (MG-QOL-15) questionnaire, the 17-item version of the Hamilton Depression Rating Scale (HAM-D) and the Hamilton Anxiety Rating Scale (HAM-A) compared with early-onset group MG patients. Female patients had higher total HAM-D and HAM-A scores than male patients among late-onset MG (*P* < 0.05), and high scores on the MG-QOL-15 questionnaire were independently associated with higher incidences of anxiety and depression. In late-onset groups, the areas under the receiver operating characteristic curves for MG-QOL-15 scores at a cutoff value of 14.5 in the anxiety and depression groups were 0.816 and 0.983, respectively.

***Research conclusions***

We found that female patients with late-onset MG were more susceptible to anxiety and depression than their male counterparts, and that higher MG-QOL-15 scores were an independent risk factor for anxiety and depression in patients with late-onset MG. An MG-QOL-15 score cutoff of 14.5 could be a good indicator for poor mental health in need of attention among late-onset MG patients.

***Research perspectives***

In the future, we will seek to determine protective factors against developing mental disorders among late-onset MG. Further follow-up and particularly studies that include healthy control groups are needed to validate the results.

**REFERENCES**

1 **Romi F**, Hong Y, Gilhus NE. Pathophysiology and immunological profile of myasthenia gravis and its subgroups. *Curr Opin Immunol* 2017; **49**: 9-13 [PMID: 28780294 DOI: 10.1016/j.coi.2017.07.006]

2 **Gilhus NE**, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. *Nat Rev Dis Primers* 2019; **5**: 30 [PMID: 31048702 DOI: 10.1038/s41572-019-0079-y]

3 **Tong O**, Delfiner L, Herskovitz S. Pain, Headache, and Other Non-motor Symptoms in Myasthenia Gravis. *Curr Pain Headache Rep* 2018; **22**: 39 [PMID: 29725917 DOI: 10.1007/s11916-018-0687-3]

4 **Li Z**, Hao Y, Han Y, Wu S, Zhu D, Liu M, Dong Q, Wang X, Guan Y. Prevalence and associated physical symptoms of depressive and anxiety symptoms in neurology outpatient clinic. *J Neurol Neurosurg Psychiatry* 2019; **90**: 1286-1287 [PMID: 30760642 DOI: 10.1136/jnnp-2018-320130]

5 **Carr AS**, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. *BMC Neurol* 2010; **10**: 46 [PMID: 20565885 DOI: 10.1186/1471-2377-10-46]

6 **Li Z**, Ruan M, Chen J, Fang Y. Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications. *Neurosci Bull* 2021; **37**: 863-880 [PMID: 33582959 DOI: 10.1007/s12264-021-00638-3]

7 **Kulaksizoglu IB**. Mood and anxiety disorders in patients with myasthenia gravis: aetiology, diagnosis and treatment. *CNS Drugs* 2007; **21**: 473-481 [PMID: 17521227 DOI: 10.2165/00023210-200721060-00004]

8 **Raggi A**, Leonardi M, Antozzi C, Confalonieri P, Maggi L, Cornelio F, Mantegazza R. Concordance between severity of disease, disability and health-related quality of life in myasthenia gravis. *Neurol Sci* 2010; **31**: 41-45 [PMID: 19816655 DOI: 10.1007/s10072-009-0167-y]

9 **Leonardi M**, Raggi A, Antozzi C, Confalonieri P, Maggi L, Cornelio F, Mantegazza R. The relationship between health, disability and quality of life in myasthenia gravis: results from an Italian study. *J Neurol* 2010; **257**: 98-102 [PMID: 19669388 DOI: 10.1007/s00415-009-5279-z]

10 **Doering S**, Henze T, Schüssler G. Coping with myasthenia gravis and implications for psychotherapy. *Arch Neurol* 1993; **50**: 617-620 [PMID: 8503799 DOI: 10.1001/archneur.1993.00540060055018]

11 **Mullins LL**, Carpentier MY, Paul RH, Sanders DB; Muscle Study Group. Disease-specific measure of quality of life for myasthenia gravis. *Muscle Nerve* 2008; **38**: 947-956 [PMID: 18697209 DOI: 10.1002/mus.21016]

12 **Padua L**, Evoli A, Aprile I, Caliandro P, Mazza S, Padua R, Tonali P. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. *Neurol Sci* 2001; **22**: 363-369 [PMID: 11917973 DOI: 10.1007/s100720100066]

13 **Yang Y**, Zhang M, Guo J, Ma S, Fan L, Wang X, Li C, Guo P, Wang J, Li H, Li Z. Quality of life in 188 patients with myasthenia gravis in China. *Int J Neurosci* 2016; **126**: 455-462 [PMID: 26000922 DOI: 10.3109/00207454.2015.1038712]

14 **Burns TM**, Grouse CK, Conaway MR, Sanders DB; mg composite and mg-qol15 study group. Construct and concurrent validation of the MG-QOL15 in the practice setting. *Muscle Nerve* 2010; **41**: 219-226 [PMID: 19941339 DOI: 10.1002/mus.21609]

15 **Burns TM**, Sadjadi R, Utsugisawa K, Gwathmey KG, Joshi A, Jones S, Bril V, Barnett C, Guptill JT, Sanders DB, Hobson-Webb L, Juel VC, Massey J, Gable KL, Silvestri NJ, Wolfe G, Cutter G, Nagane Y, Murai H, Masuda M, Farrugia ME, Carmichael C, Birnbaum S, Hogrel JY, Nafissi S, Fatehi F, Ou C, Liu W, Conaway M. International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r. *Muscle Nerve* 2016; **54**: 1015-1022 [PMID: 27220659 DOI: 10.1002/mus.25198]

16 **Ybarra MI**, Kummer A, Frota ER, Oliveira JT, Gomez RS, Teixeira AL. Psychiatric disorders in myasthenia gravis. *Arq Neuropsiquiatr* 2011; **69**: 176-179 [PMID: 21537555 DOI: 10.1590/s0004-282x2011000200006]

17 **Paul RH**, Cohen RA, Goldstein JM, Gilchrist JM. Severity of mood, self-evaluative, and vegetative symptoms of depression in myasthenia gravis. *J Neuropsychiatry Clin Neurosci* 2000; **12**: 499-501 [PMID: 11083168 DOI: 10.1176/jnp.12.4.499]

18 **Law C**, Flaherty CV, Bandyopadhyay S. A Review of Psychiatric Comorbidity in Myasthenia Gravis. *Cureus* 2020; **12**: e9184 [PMID: 32802619 DOI: 10.7759/cureus.9184]

19 **Blum S**, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P. Clinical features and impact of myasthenia gravis disease in Australian patients. *J Clin Neurosci* 2015; **22**: 1164-1169 [PMID: 26021730 DOI: 10.1016/j.jocn.2015.01.022]

20 **Deymeer F**. Myasthenia gravis: MuSK MG, late-onset MG and ocular MG. *Acta Myol* 2020; **39**: 345-352 [PMID: 33458590 DOI: 10.36185/2532-1900-038]

21 **Aarli JA**. Myasthenia gravis in the elderly: Is it different? *Ann N Y Acad Sci* 2008; **1132**: 238-243 [PMID: 18567874 DOI: 10.1196/annals.1405.040]

22 **Alkhawajah NM**, Oger J. Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing. *Muscle Nerve* 2013; **48**: 705-710 [PMID: 23893883 DOI: 10.1002/mus.23964]

23 **Gilhus NE**, Nacu A, Andersen JB, Owe JF. Myasthenia gravis and risks for comorbidity. *Eur J Neurol* 2015; **22**: 17-23 [PMID: 25354676 DOI: 10.1111/ene.12599]

24 **Sanders DB**, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P. International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology* 2016; **87**: 419-425 [PMID: 27358333 DOI: 10.1212/WNL.0000000000002790]

25 **Burns TM**, Conaway M, Sanders DB; MG Composite and MG-QOL15 Study Group. The MG Composite: A valid and reliable outcome measure for myasthenia gravis. *Neurology* 2010; **74**: 1434-1440 [PMID: 20439845 DOI: 10.1212/WNL.0b013e3181dc1b1e]

26 **Wolfe GI**, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. *Neurology* 1999; **52**: 1487-1489 [PMID: 10227640 DOI: 10.1212/wnl.52.7.1487]

27 **Burns TM**, Conaway MR, Cutter GR, Sanders DB; Muscle Study Group. Less is more, or almost as much: a 15-item quality-of-life instrument for myasthenia gravis. *Muscle Nerve* 2008; **38**: 957-963 [PMID: 18642357 DOI: 10.1002/mus.21053]

28 **HAMILTON M**. The assessment of anxiety states by rating. *Br J Med Psychol* 1959; **32**: 50-55 [PMID: 13638508 DOI: 10.1111/j.2044-8341.1959.tb00467.x]

29 **HAMILTON M**. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960; **23**: 56-62 [PMID: 14399272 DOI: 10.1136/jnnp.23.1.56]

30 **Miao X**, Lian Z, Liu J, Chen H, Shi Z, Li M, Zhou H, Hu X, Yang R. Translation, cross-cultural adaptation, and validation of the chinese version of the 15-item myasthenia gravis quality of life questionnaire. *Muscle Nerve* 2019; **59**: 95-99 [PMID: 30055010 DOI: 10.1002/mus.26313]

31 **Zheng YP**, Zhao JP, Phillips M, Liu JB, Cai MF, Sun SQ, Huang MF. Validity and reliability of the Chinese Hamilton Depression Rating Scale. *Br J Psychiatry* 1988; **152**: 660-664 [PMID: 3167442 DOI: 10.1192/bjp.152.5.660]

32 **Bagby RM**, Ryder AG, Schuller DR, Marshall MB. The Hamilton Depression Rating Scale: has the gold standard become a lead weight? *Am J Psychiatry* 2004; **161**: 2163-2177 [PMID: 15569884 DOI: 10.1176/appi.ajp.161.12.2163]

33 **Leung CM**, Wing YK, Kwong PK, Lo A, Shum K. Validation of the Chinese-Cantonese version of the hospital anxiety and depression scale and comparison with the Hamilton Rating Scale of Depression. *Acta Psychiatr Scand* 1999; **100**: 456-461 [PMID: 10626925 DOI: 10.1111/j.1600-0447.1999.tb10897.x]

34 **Gilhus NE**, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. *Lancet Neurol* 2015; **14**: 1023-1036 [PMID: 26376969 DOI: 10.1016/S1474-4422(15)00145-3]

35 **Thompson E**. Hamilton Rating Scale for Anxiety (HAM-A). *Occup Med (Lond)* 2015; **65**: 601 [PMID: 26370845 DOI: 10.1093/occmed/kqv054]

36 **Zimmerman M**, Martinez JH, Young D, Chelminski I, Dalrymple K. Severity classification on the Hamilton Depression Rating Scale. *J Affect Disord* 2013; **150**: 384-388 [PMID: 23759278 DOI: 10.1016/j.jad.2013.04.028]

37 **Winter Y**, Schepelmann K, Spottke AE, Claus D, Grothe C, Schröder R, Heuss D, Vielhaber S, Tackenberg B, Mylius V, Reese JP, Kiefer R, Schrank B, Oertel WH, Dodel R. Health-related quality of life in ALS, myasthenia gravis and facioscapulohumeral muscular dystrophy. *J Neurol* 2010; **257**: 1473-1481 [PMID: 20383521 DOI: 10.1007/s00415-010-5549-9]

38 **Braz NFT**, Rocha NP, Vieira ÉLM, Barbosa IG, Gomez RS, Kakehasi AM, Teixeira AL. Muscle strength and psychiatric symptoms influence health-related quality of life in patients with myasthenia gravis. *J Clin Neurosci* 2018; **50**: 41-44 [PMID: 29396072 DOI: 10.1016/j.jocn.2018.01.011]

39 **Alanazy MH**, Binabbad RS, Alromaih NI, Almansour RA, Alanazi SN, Alhamdi MF, Alazwary N, Muayqil T. Severity and depression can impact quality of life in patients with myasthenia gravis. *Muscle Nerve* 2020; **61**: 69-73 [PMID: 31573094 DOI: 10.1002/mus.26719]

40 **Burns TM**, Grouse CK, Wolfe GI, Conaway MR, Sanders DB; MG Composite and MG-OL15 Study Group. The MG-QOL15 for following the health-related quality of life of patients with myasthenia gravis. *Muscle Nerve* 2011; **43**: 14-18 [PMID: 21082698 DOI: 10.1002/mus.21883]

41 **Stojanov A**, Milošević V, Đorđević G, Stojanov J. Quality of Life of Myasthenia Gravis Patients in Regard to Epidemiological and Clinical Characteristics of the Disease. *Neurologist* 2019; **24**: 115-120 [PMID: 31246720 DOI: 10.1097/NRL.0000000000000238]

42 **Masuda M**, Utsugisawa K, Suzuki S, Nagane Y, Kabasawa C, Suzuki Y, Shimizu Y, Utsumi H, Fujihara K, Uchiyama S, Suzuki N. The MG-QOL15 Japanese version: validation and associations with clinical factors. *Muscle Nerve* 2012; **46**: 166-173 [PMID: 22806364 DOI: 10.1002/mus.23398]

43 **Green T**, Flash S, Reiss AL. Sex differences in psychiatric disorders: what we can learn from sex chromosome aneuploidies. *Neuropsychopharmacology* 2019; **44**: 9-21 [PMID: 30127341 DOI: 10.1038/s41386-018-0153-2]

44 **Gobinath AR**, Choleris E, Galea LA. Sex, hormones, and genotype interact to influence psychiatric disease, treatment, and behavioral research. *J Neurosci Res* 2017; **95**: 50-64 [PMID: 27870452 DOI: 10.1002/jnr.23872]

45 **Bangasser DA**, Valentino RJ. Sex differences in stress-related psychiatric disorders: neurobiological perspectives. *Front Neuroendocrinol* 2014; **35**: 303-319 [PMID: 24726661 DOI: 10.1016/j.yfrne.2014.03.008]

46 **Hammen C**, Brennan PA, Keenan-Miller D, Hazel NA, Najman JM. Chronic and acute stress, gender, and serotonin transporter gene-environment interactions predicting depression symptoms in youth. *J Child Psychol Psychiatry* 2010; **51**: 180-187 [PMID: 19811586 DOI: 10.1111/j.1469-7610.2009.02177.x]

47 **Ming QS**, Zhang Y, Chai QL, Chen HY, Hou CJ, Wang MC, Wang YP, Cai L, Zhu XZ, Yi JY, Yao SQ. Interaction between a serotonin transporter gene promoter region polymorphism and stress predicts depressive symptoms in Chinese adolescents: a multi-wave longitudinal study. *BMC Psychiatry* 2013; **13**: 142 [PMID: 23683292 DOI: 10.1186/1471-244X-13-142]

48 **Dong D**, Chong MK, Wu Y, Kaminski H, Cutter G, Xu X, Li H, Zhao C, Yin J, Yu S, Zhu J. Gender differences in quality of life among patients with myasthenia gravis in China. *Health Qual Life Outcomes* 2020; **18**: 296 [PMID: 32883289 DOI: 10.1186/s12955-020-01549-z]

49 **Boldingh MI**, Maniaol AH, Brunborg C, Weedon-Fekjær H, Verschuuren JJ, Tallaksen CM. Increased risk for clinical onset of myasthenia gravis during the postpartum period. *Neurology* 2016; **87**: 2139-2145 [PMID: 27770065 DOI: 10.1212/WNL.0000000000003339]

50 **Leker RR**, Karni A, Abramsky O. Exacerbation of myasthenia gravis during the menstrual period. *J Neurol Sci* 1998; **156**: 107-111 [PMID: 9559997 DOI: 10.1016/s0022-510x(98)00031-8]

51 **Schneider-Gold C**, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. *Ther Adv Neurol Disord* 2019; **12**: 1756286419832242 [PMID: 30854027 DOI: 10.1177/1756286419832242]

52 **Lee I**, Kaminski HJ, McPherson T, Feese M, Cutter G. Gender differences in prednisone adverse effects: Survey result from the MG registry. *Neurol Neuroimmunol Neuroinflamm* 2018; **5**: e507 [PMID: 30345333 DOI: 10.1212/NXI.0000000000000507]

53 **Kulkantrakorn K**, Sawanyawisuth K, Tiamkao S. Factors correlating quality of life in patients with myasthenia gravis. *Neurol Sci* 2010; **31**: 571-573 [PMID: 20461430 DOI: 10.1007/s10072-010-0285-6]

54 **Rostedt A**, Padua L, Stålberg EV. Correlation between regional myasthenic weakness and mental aspects of quality of life. *Eur J Neurol* 2006; **13**: 191-193 [PMID: 16490052 DOI: 10.1111/j.1468-1331.2006.01149.x]

55 **Wolfe GI**, Kaminski HJ, Sonnett JR, Aban IB, Kuo HC, Cutter GR. Randomized trial of thymectomy in myasthenia gravis. *J Thorac Dis* 2016; **8**: E1782-E1783 [PMID: 28149641 DOI: 10.21037/jtd.2016.12.80]

56 **Wang L**, Huan X, Xi JY, Wu H, Zhou L, Lu JH, Zhang TS, Zhao CB. Immunosuppressive and monoclonal antibody treatment for myasthenia gravis: A network meta-analysis. *CNS Neurosci Ther* 2019; **25**: 647-658 [PMID: 30809966 DOI: 10.1111/cns.13110]

57 **Szczudlik P**, Sobieszczuk E, Szyluk B, Lipowska M, Kubiszewska J, Kostera-Pruszczyk A. Determinants of Quality of Life in Myasthenia Gravis Patients. *Front Neurol* 2020; **11**: 553626 [PMID: 33071942 DOI: 10.3389/fneur.2020.553626]

58 **Zivković SA**, Clemens PR, Lacomis D. Characteristics of late-onset myasthenia gravis. *J Neurol* 2012; **259**: 2167-2171 [PMID: 22476514 DOI: 10.1007/s00415-012-6478-6]

59 **Stacy S**, Williams EL, Standifer NE, Pasquali A, Krolick KA, Infante AJ, Kraig E. Maintenance of immune tolerance to a neo-self acetylcholine receptor antigen with aging: implications for late-onset autoimmunity. *J Immunol* 2010; **184**: 6067-6075 [PMID: 20435934 DOI: 10.4049/jimmunol.0901618]

60 **Watad A**, Bragazzi NL, Adawi M, Amital H, Toubi E, Porat BS, Shoenfeld Y. Autoimmunity in the Elderly: Insights from Basic Science and Clinics - A Mini-Review. *Gerontology* 2017; **63**: 515-523 [PMID: 28768257 DOI: 10.1159/000478012]

61 **Suzuki S**, Utsugisawa K, Nagane Y, Satoh T, Kuwana M, Suzuki N. Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. *J Neuroimmunol* 2011; **230**: 148-152 [PMID: 21074862 DOI: 10.1016/j.jneuroim.2010.10.023]

62 **Hellmann MA**, Mosberg-Galili R, Steiner I. Myasthenia gravis in the elderly. *J Neurol Sci* 2013; **325**: 1-5 [PMID: 23218585 DOI: 10.1016/j.jns.2012.10.028]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the ethics committee of The First Affiliated Hospital of the Sun Yat-sen University.

**Informed consent statement:** All study participants provided informed written consent prior to the scale-based clinical examinations.

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 1, 2021

**First decision:** December 4, 2021

**Article in press:** February 22, 2022

**Specialty type:** Psychiatry

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): 0

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Goh KK, Setiawati Y **S-Editor:** Zhang H **L-Editor:** Kerr C **P-Editor:** Zhang H

**Figure Legends**

****

**Figure 1** **Hamilton anxiety rating and the** **Hamilton depression rating scores according to age of onset.** A: The median (interquartile range) of Hamilton anxiety rating (HAM-A scale scores in early-onset and late-onset groups were 5 (5.5) and 8.5 (7.5), respectively. The HAM-A scale score was significantly higher in the late-onset group than early-onset group (*P* < 0.001); B: The Hamilton depression rating (HAM-D) score levels in early-onset and late-onset groups were 7 (8) and 10.5 (7.75), respectively. The HAM-D scale score was significantly higher in the late-onset group than early-onset group (*P* = 0.018). *P* value was calculated using Mann-Whitney *U* test.

****

**Figure 2 Hamilton anxiety rating and the Hamilton depression rating scores according to age of onset and sex.** A: The median (interquartile range) of Hamilton anxiety rating (HAM-A scale levels in late-onset groups were 3 (6), and 9 (8), respectively, and HAM-A scale scores were significantly higher in late-onset group than early-onset group in women (*P* < 0.001); B: The Hamilton depression rating (HAM-D) score levels in early-onset and late-onset groups were 7 (7) and 11 (10), respectively, and HAM-D scale score was significantly higher in late-onset group than early-onset group in women (*P* = 0.001). There were no significant differences in men for both HAM-A and HAM-D scale scores. *P* value was calculated using Mann-Whitney *U* test.

**Table 1 Comparison between early-onset and late-onset groups**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Total patients (*n* = 105)** | **Early-onset (*n* = 63)** | **Late-onset (*n* = 42)** | ***P* value** |
| Gender (*n*, %)1 |  |  | | |
| Male | 49 (46.67) | 26 (41.27) | 23 (54.76) |  |
| Female | 56 (53.34) | 37 (58.73) | 19 (45.24) | 0.231 |
| Marital status (*n*, %)2 |  |  | | |
| Married | 63 (60.0) | 33 (52.38) | 30 (71.43) | 0.067 |
| Single (unmarried/divorced/widowed) | 42 (40.0) | 30 (47.62) | 12 (28.57) |
| Education (*n*, %)2 |  |  | | |
| Primary school and below | 26 (24.76) | 12 (19.05) | 14 (33.33) | 0.073 |
| Secondary school | 44 (41.90) | 25 (39.68) | 19 (45.24) |
| College and above | 35 (33.33) | 26 (41.27) | 9 (21.43) |
| Career change due to illness (*n*, %)2 |  |  |  | 0.955 |
| No change | 69 (65.71) | 41 (65.08) | 28 (66.67) |
| Leave of absence | 24 (22.86) | 15 (23.81) | 9 (21.43) |
| Transfer/unemployment | 12 (11.43) | 7 (11.11) | 5 (11.90) |
| BMI (kg/m2)3 | 21.71 (5.77) | 20.51 (4.21) | 24.36 (4.53) | < 0.001c |
| Disease duration (mo)3 | 5.00(12.21) | 7.00(13.34) | 4.00(8.50) | 0.016a |
| MGFA classification at evaluating (*n*, %)1 |  |  | | |
| Ⅰ | 28 (26.67) | 21 (33.33) | 7 (16.67) |  |
| Ⅱ | 40 (38.10) | 22 (34.92) | 18 (42.86) |  |
| Ⅲ | 31 (29.52) | 16 (25.40) | 15 (35.71) |  |
| Ⅳ | 6 (5.71) | 4 (6.35) | 2 (4.76) | 0.255 |
| Thymectomy (*n*, %)2 | 44 (41.90) | 28 (44.44) | 16 (38.10) | 0.551 |
| Comorbidities (*n*, %)2 | 49 (46.67) | 32 (50.79) | 17 (40.48) | 0.299 |
| Inducing factor (*n*, %)1 |  |  | | |
| Respiratory infection | 12 (11.43) | 6 (9.52) | 6 (14.29) |  |
| Overfatigue | 3 (2.86) | 1 (1.59) | 2 (4.76) |  |
| No triggers | 90 (85.71) | 56 (88.89) | 34 (80.95) | 0.470 |
| Clinical features |  |  | | |
| Onset symptom |
| Blepharoptosis (*n*, %)2 | 97 (92.38) | 59 (93.65) | 38 (90.48) | 0.711 |
| [[Dysphagia](javascript:;)](javascript:;) (*n*, %)2 | 50 (47.62) | 29 (46.03) | 21 (50.00) | 0.842 |
| Limb muscle weakness (*n*, %)2 | 55 (52.38) | 31 (49.21) | 24 (57.14) | 0.550 |
| [Dyspnea](javascript:;) (*n*, %)2 | 15 (14.29) | 5 (7.94) | 10 (23.81) | 0.043a |
| Serum antibody (nmol/L) 3 |  |  | | |
| Anti-AChR Ab | 9.54 (25.98) | 3.11 (17.98) | 17.51 (27.45) | 0.002b |
| Anti-MuSK Ab | 0 (1.13) | 0.31 (2.17) | 0 (0) | 0.098 |
| Seronegative (*n*, %)2 | 16 (15.24) | 11 (17.46) | 5 (11.90) | 0.582 |
| Immunotherapy at evaluating |  |  | | |
| Glucocorticoids (*n*, %)2 | 76 (72.38) | 49 (77.78) | 27 (64.29) | 0.181 |
| Azathioprine (*n*, %)2 | 31 (29.52) | 19 (30.16) | 12 (28.57) | 0.861 |
| Tacrolimus (*n*, %)2 | 8 (7.62) | 3 (4.76) | 5 (11.90) | 0.262 |
| Leflunomide (*n*, %)2 | 22 (20.95) | 13 (20.63) | 9 (21.43) | 0.922 |
| No immunotherapy (*n*, %)2 | 53 (50.48) | 32 (50.79) | 21 (50.00) | 0.936 |
| Neuropsychological scales |  |  | | |
| MGC3 | 6.00 (6.50) | 6.00 (6.00) | 7.00 (7.00) | 0.103 |
| ADL3 | 3.00 (3.00) | 3.00 (4.00) | 3.00 (2.00) | 0.960 |
| QOL-153 | 14.00 (15.00) | 12.00 (13.50) | 16.00 (20.00) | 0.027a |
| HAM-A3 | 6.00 (7.00) | 5.00 (5.50) | 8.50 (7.50) | < 0.001c |
| HAM-D3 | 8.00 (7.00) | 7.00 (8.00) | 10.50 (7.75) | 0.018a |

1*n* (%), Fisher’s exact test.

2*n* (%), Pearson’s *χ*2 test.

3Median (25%Q, 75%Q), Mann-Whitney *U* test.

a*P* < 0.05.

b*P* < 0.01.

c*P* < 0.001.

BMI: Body mass index; ADL: Activities of daily living scale; MGC: Myasthenia Gravis Composite scale; MG-QOL-15: Myasthenia Gravis Quality of Life 15 questionnaire; HAM-A: Hamilton Anxiety Rating Scale; HAM-D: Hamilton Depression Rating Scale.

**Table 2 Correlation between clinical features and age at onset**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Clinical features** | **Correlation** | **95%CI** | ***t*** | ***P* value** |
| Disease duration | -0.59 | -0.70, -0.446 | -7.370 | < 0.001c |
| BMI | 0.41 | 0.233, 0.555 | 4.520 | < 0.001c |
| Anti-AChR Ab | 0.31 | 0.128, 0.475 | 3.335 | 0.001b |
| QOL-15 | 0.32 | 0.133, 0.479 | 3.383 | 0.001b |
| HAM-A | 0.41 | 0.236, 0.557 | 4.548 | < 0.001c |
| HAM-D | 0.26 | 0.074, 0.432 | 2.759 | 0.007b |

a*P* < 0.05.

b*P* < 0.01.

c*P* < 0.001.

BMI: Body mass index; MG-QOL-15: Myasthenia Gravis Quality of Life 15 questionnaire; HAM-A: Hamilton Anxiety Rating Scale; HAM-D: Hamilton Depression Rating Scale.

**Table 3** **Multivariate** **logistic model of the clinical determinants of anxiety/depression in myasthenia gravis patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Model 1** | | **Model 2** | |
| **OR (95%CI)** | ***P* value** | **OR (95%CI)** | ***P* value** |
| Anxiety |  |  |  |  |
| Gender | 0.96 (0.45-2.07) | 0.917 | 0.65 (0.25-1.68) | 0.372 |
| Age at onset | 1.04 (1.02-1.07) | 0.002b | 1.02 (0.99-1.05) | 0.305 |
| Disease duration | 0.93 (0.88-0.98) | 0.070 | 0.97 (0.90-1.04) | 0.414 |
| BMI | 1.10 (0.99-1.23) | 0.075 | 1.05 (0.92-1.21) | 0.485 |
| Anti-AChR Ab | 1.02 (1.00-1.05) | 0.092 | 1.02 (0.99-1.05) | 0.274 |
| QOL-15 | 1.10 (1.05-1.16) | < 0.001c | 1.10 (1.04-1.15) | < 0.001c |
| Depression |  |  |  |  |
| Gender | 0.82 (0.36-1.82) | 0.636 | 0.56 (0.19-1.64) | 0.293 |
| Age at onset | 1.03 (1.00-1.06) | 0.022a | 1.03 (0.99-1.06) | 0.162 |
| Disease duration | 0.98 (0.93-1.03) | 0.418 | 1.06 (0.98-1.15) | 0.172 |
| BMI | 1.05 (0.93-1.17) | 0.440 | 0.97 (0.83-1.13) | 0.678 |
| Anti-AChR Ab | 1.10 (0.99-1.04) | 0.387 | 1.01 (0.97-1.05) | 0.582 |
| QOL-15 | 1.19 (1.10-1.28) | < 0.001c | 1.20 (1.10-1.30) | < 0.001c |

a*P* < 0.05.

b*P* < 0.01.

c*P* < 0.001.

Model 1: Unadjusted; Model 2: Adjusted for possible confounders including gender, age at onset, body mass index, and anti-acetylcholine receptor antibody. BMI: Body mass index; QOL-15: Myasthenia Gravis Quality of Life 15 questionnaire; OR = exp (β).



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**